Human Immunodeficiency Virus Therapeutics Market Size, Share & Trends Report

Human Immunodeficiency Virus Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs), Non-NRTIs, Entry & Fusion, Protease), And Segment Forecasts, 2018 - 2025

  • Report ID: GVR-1-68038-210-5
  • Number of Pages: 75
  • Format: Electronic (PDF)
  • Historical Range: 2014 - 2015
  • Industry: Healthcare

Market Segmentation

  • Global HIV-1 Therapeutics Drug Class Outlook (USD Million, 2014 - 2025)
    • Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
    • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • Entry and Fusion Inhibitors
    • Protease Inhibitors (PIs)
    • Integrase Inhibitors
    • Coreceptor Antagonists
  • Global HIV-1 Therapeutics Regional Outlook (USD Million, 2014 - 2025)
    • North America
      • The U.S.
        • U.S.Drug Class Outlook (USD Million, 2014 - 2025)
        • Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
        • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
        • Entry and Fusion Inhibitors
        • Protease Inhibitors (PIs)
        • Integrase Inhibitors
        • Coreceptor Antagonists
      • Canada
        • Canada Drug Class Outlook (USD Million, 2014 - 2025)
        • Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
        • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
        • Entry and Fusion Inhibitors
        • Protease Inhibitors (PIs)
        • Integrase Inhibitors
        • Coreceptor Antagonists
    • Europe
      • UK
        • UK Drug Classes Outlook (USD Million, 2014 - 2025)
        • Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
        • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
        • Entry and Fusion Inhibitors
        • Protease Inhibitors (PIs)
        • Integrase Inhibitors
        • Coreceptor Antagonists
      • Germany
        • Germany Drug Classes Outlook (USD Million, 2014 - 2025)
        • Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
        • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
        • Entry and Fusion Inhibitors
        • Protease Inhibitors (PIs)
        • Integrase Inhibitors
        • Coreceptor Antagonists
    • Asia Pacific
      • Japan
        • Japan Drug Classes Outlook (USD Million, 2014 - 2025)
        • Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
        • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
        • Entry and Fusion Inhibitors
        • Protease Inhibitors (PIs)
        • Integrase Inhibitors
        • Coreceptor Antagonists
      • China
        • China Drug Classes Outlook (USD Million, 2014 - 2025)
        • Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
        • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
        • Entry and Fusion Inhibitors
        • Protease Inhibitors (PIs)
        • Integrase Inhibitors
        • Coreceptor Antagonists
      • India
        • India Drug Classes Outlook (USD Million, 2014 - 2025)
        • Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
        • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
        • Entry and Fusion Inhibitors
        • Protease Inhibitors (PIs)
        • Integrase Inhibitors
        • Coreceptor Antagonists
    • Latin America
      • Mexico
        • Mexico Drug Classes Outlook (USD Million, 2014 - 2025)
        • Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
        • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
        • Entry and Fusion Inhibitors
        • Protease Inhibitors (PIs)
        • Integrase Inhibitors
        • Coreceptor Antagonists
      • Brazil
        • Brazil Drug Classes Outlook (USD Million, 2014 - 2025)
        • Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
        • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
        • Entry and Fusion Inhibitors
        • Protease Inhibitors (PIs)
        • Integrase Inhibitors
        • Coreceptor Antagonists
    • MEA
      • South Africa
        • South Africa Drug Classes Outlook (USD Million, 2014 - 2025)
        • Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
        • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
        • Entry and Fusion Inhibitors
        • Protease Inhibitors (PIs)
        • Integrase Inhibitors
        • Coreceptor Antagonists
What questions do you have? Get quick response from our industry experts. Request a Free Consultation
pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon